Guardant Health, Inc. (GH) Guidance & Earnings Results
On 2026-07-30 Guardant Health, Inc. raised guidance: "FY2026 revenue raised to $1.34-1.36B from $1.30-1.32B; Oncology revenue growth ~30% (prior 28-29%); Oncology volume growth ~50% (prior ~35%); Screening revenue $218-230M with 270-285K Shield…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GHGuardant Health, Inc.Follow GH — free
—
Price chart with a free account
- Market cap
- 22.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Raised | FY2026 revenue raised to $1.34-1.36B from $1.30-1.32B; Oncology revenue growth ~30% (prior 28-29%); Oncology volume growth ~50% (prior ~35%); Screening revenue $218-230M with 270-285K Shield tests · full year |
| 7 May 26 | Raised | Full year 2026 revenue guidance raised to $1.30-$1.32B from $1.25-$1.28B · full year |
| 19 Feb 26 | Raised | FY2026 total revenue growth of 27-30% YoY |
| 29 Oct 25 | Raised | FY2025 revenue guidance raised from $915-925M to $965-970M (31% YoY growth) · full year |
| 30 Jul 25 | Raised | FY2025 revenue raised to $915-925M from prior (not stated); representing growth of 24% to 25% · full year |
Guardant Health, Inc. — questions
- What guidance did Guardant Health, Inc. give?
- On 2026-07-30: "FY2026 revenue raised to $1.34-1.36B from $1.30-1.32B; Oncology revenue growth ~30% (prior 28-29%); Oncology volume growth ~50% (prior ~35%); Screening revenue $218-230M with 270-285K Shield tests"
- When does Guardant Health, Inc. report earnings?
- Guardant Health, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Guardant Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.